Conjugated antisense compounds and their use
US-10570169-B2 · Feb 25, 2020 · US
US11440932B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11440932-B2 |
| Application number | US-201716492005-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 27, 2017 |
| Priority date | Mar 9, 2017 |
| Publication date | Sep 13, 2022 |
| Grant date | Sep 13, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a compound of formula (I): (I) as defined in the description. The present invention also relates to a method for extracting biological membrane-associated membrane proteins, comprising a step of bringing an aqueous solution of biological membrane-associated membrane proteins into contact with at least one compound of the invention. The present invention also relates to a method for stabilizing membrane proteins in solution in an aqueous solution, comprising a step (i) consisting in bringing an aqueous solution of a membrane protein in solution into contact with at least one compound of the invention.
Opening claim text (preview).
The invention claimed is: 1. A compound or a pharmaceutically acceptable salt thereof, chosen from: 2. A process for extracting membrane proteins, comprising bringing an aqueous solution of membrane proteins associated with a biological membrane into contact with at least one compound or a pharmaceutically acceptable salt thereof chosen from: 3. The process according to claim 2 , wherein the membrane protein is present in a biological membrane fraction originating from a prokaryotic or eukaryotic organism. 4. The process according to claim 2 , wherein the membrane protein is a transport protein. 5. The process according to claim 4 , wherein the transport protein is an ABC transporter selected from the group consisting of P-glycoproteins (Pgp/ABCB1), MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2 and BmrA. 6. The process according to claim 2 , wherein the bringing of an aqueous solution comprising the membrane protein to be extracted into contact with the at least one of the compounds or a pharmaceutically acceptable salt thereof is carried out at a pH ranging from 5.5 to 10. 7. A process for stabilizing membrane proteins in solution in an aqueous solution, comprising bringing an aqueous solution of an extracted membrane protein into contact with at least one compound or a pharmaceutically acceptable salt thereof chosen from: 8. The process according to claim 7 , wherein the membrane proteins are extracted by bringing an aqueous solution of membrane proteins associated with a biological membrane into contact with at least one of the compounds or a pharmaceutically acceptable salt thereof. 9. The process according to claim 7 , wherein said protein in solution is stabilized at a temperature of from 0° C. to 10° C. for a duration of greater than 1 day. 10. The process according to claim 7 , wherein the membrane proteins are extracted by detergent.
having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups (peptides C07K) · CPC title
attached to a sulfur, selenium or tellurium atom of a saccharide radical · CPC title
1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles · CPC title
by extraction or solubilisation · CPC title
having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated (peptides C07K) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.